Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) (TNFAIP3)

Tumor necrosis factor alpha-induced protein 3 (TNFAIP3), also known as A20, is a pivotal ubiquitin-editing enzyme that serves as a master negative regulator of the NF-κB signaling pathway (PubMed, 2019; Frontiers in Immunology, 2018). It functions through a dual mechanism, utilizing its N-terminal ovarian tumor (OTU) domain for deubiquitinase activity and its C-terminal zinc finger domains for E3 ubiquitin ligase activity to modify key signaling mediators like RIPK1 and TRAF6 (Frontiers in Immunology, 2018; Ma'ayan Lab, 2012). By terminating pro-inflammatory signals and regulating TNF-induced apoptosis, TNFAIP3 maintains immune homeostasis and prevents chronic inflammation (Wikipedia, 2024; ResearchGate, 2024). Genetic variants and loss-of-function mutations in TNFAIP3 are strongly associated with various autoimmune and autoinflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus, and A20 haploinsufficiency (HA20) (Frontiers in Immunology, 2018; PubMed, 2020). In the context of drug therapy, TNFAIP3 expression is modulated by glucocorticoids and beta-agonists, while its dysregulation can contribute to resistance against treatments like tamoxifen or anti-TNF agents (Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2009; PubMed, 2017). The TNFAIP3-NF-κB pathway represents a critical signaling axis where TNFAIP3 acts as a druggable node to control inflammatory output (PubMed, 2019).

Other names

A20OTUD7CTNFA1P2AISBLTNF alpha-induced protein 3

TNFAIP3 acts as a negative feedback regulator of the NF-κB pathway by exerting dual ubiquitin-editing activities: it removes K63-linked polyubiquitin chains (deubiquitinase activity) and adds K48-linked polyubiquitin chains (E3 ligase activity) to key signaling proteins such as RIPK1, TRAF6, and NEMO, leading to their inactivation or proteasomal degradation (Frontiers in Immunology, 2018; PubMed, 2020).